| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC3902 |
| Trial ID | NCT06458595 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | KH658 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase I/II Study to Evaluate the Tolerability, Safety and Efficacy of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD). |
| Year | 2024 |
| Country | China |
| Company sponsor | Chengdu Origen Biotechnology Co., Ltd. |
| Other ID(s) | KH658-40101 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||